Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Acquisitions (2020 - 2021)

Historic Acquisitions for Anika Therapeutics (ANIK) over the last 2 years, with Q4 2021 value amounting to $113000.0.

  • Anika Therapeutics' Acquisitions fell 8477.09% to $113000.0 in Q4 2021 from the same period last year, while for Sep 2022 it was $113000.0, marking a year-over-year decrease of 8977.38%. This contributed to the annual value of $476000.0 for FY2021, which is 9949.68% down from last year.
  • As of Q4 2021, Anika Therapeutics' Acquisitions stood at $113000.0, which was down 8477.09% from $11000.0 recorded in Q3 2021.
  • In the past 5 years, Anika Therapeutics' Acquisitions ranged from a high of $93.0 million in Q1 2020 and a low of $2000.0 during Q2 2021